High-risk MDS after HMAs

por Adès, Lionel
Publicado 2019

Machine learning-based improvement of MDS-CBC score brings platelets into the limelight to optimize smear review in the hematology laboratory

por Zhu, Jaja, Lemaire, Pierre, Mathis, Stéphanie, Ronez, Emily, Clauser, Sylvain, Jondeau, Katayoun, Fenaux, Pierre, Adès, Lionel, Bardet, Valérie
Publicado 2022

Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study()

por de Renzis, Benoit, Mansat-De Mas, Veronique, Wattel, Eric, Beyne-Rauzy, Odile, Knoops, Laurent, Cabrespine, Aurélie, Azgui, Zahia, Ades, Lionel, Kiladjian, Jean-Jacques, Fenaux, Pierre
Publicado 2013

Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes

por Zeidner, Joshua F., Mazerolle, Flora, Norton, Jonathan, Regnault, Antoine, Kristo, Fjoralba, Romero, Heather, Fram, Robert J., Faller, Douglas V., Dalal, Mehul, Ades, Lionel, Sekeres, Mikkael A.
Publicado 2022

Estimating the treatment effect from non-randomized studies: The example of reduced intensity conditioning allogeneic stem cell transplantation in hematological diseases

por Resche-Rigon, Matthieu, Pirracchio, Romain, Robin, Marie, De Latour, Regis Peffault, Sibon, David, Ades, Lionel, Ribaud, Patricia, Fermand, Jean-Paul, Thieblemont, Catherine, Socié, Gérard, Chevret, Sylvie
Publicado 2012

Hepatosplenic Candidiasis in Patients With Hematological Malignancies: A 13-Year Retrospective Cohort Study

por Boussen, Inès, Lisan, Quentin, Raffoux, Emmanuel, Di Blasi, Roberta, Boissel, Nicolas, Oksenhendler, Eric, Adès, Lionel, Xhaard, Aliénor, Bretagne, Stéphane, Alanio, Alexandre, Molina, Jean-Michel, Denis, Blandine
Publicado 2022

Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis

por Cerrano, Marco, Chevret, Sylvie, Raffoux, Emmanuel, Rabian, Florence, Sébert, Marie, Valade, Sandrine, Itzykson, Raphael, Lemiale, Virginie, Adès, Lionel, Boissel, Nicolas, Dombret, Hervé, Azoulay, Elie, Lengliné, Etienne
Publicado 2023

Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes

por Cluzeau, Thomas, McGraw, Kathy L., Irvine, Brittany, Masala, Erico, Ades, Lionel, Basiorka, Ashley A., Maciejewski, Jaroslaw, Auberger, Patrick, Wei, Sheng, Fenaux, Pierre, Santini, Valeria, List, Alan
Publicado 2017

Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications

por Fodil, Sofiane, Chevret, Sylvie, Rouzaud, Camille, Valade, Sandrine, Rabian, Florence, Mariotte, Eric, Raffoux, Emmanuel, Itzykson, Raphael, Boissel, Nicolas, Sébert, Marie, Adès, Lionel, Zafrani, Lara, Azoulay, Elie, Lengliné, Etienne
Publicado 2022

Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia

por Lehmann-Che, Jacqueline, Bally, Cécile, Letouzé, Eric, Berthier, Caroline, Yuan, Hao, Jollivet, Florence, Ades, Lionel, Cassinat, Bruno, Hirsch, Pierre, Pigneux, Arnaud, Mozziconacci, Marie-Joelle, Kogan, Scott, Fenaux, Pierre, de Thé, Hugues
Publicado 2018

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Fra...

por Ades, Lionel, Prebet, Thomas, Stamatoullas, Aspasia, Recher, Christian, Guieze, Romain, Raffoux, Emmanuel, Bouabdallah, Krimo, Hunault, Mathilde, Wattel, Eric, Stalnikiewicz, Laure, Toma, Andrea, Dombret, Hervé, Vey, Norbert, Sebert, Marie, Gardin, Claude, Chaffaut, Cendrine, Chevret, Sylvie, Fenaux, Pierre
Publicado 2017

Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia

por Maslah, Nabih, Salomao, Norman, Drevon, Louis, Verger, Emmanuelle, Partouche, Nicolas, Ly, Pierre, Aubin, Philippe, Naoui, Nadia, Schlageter, Marie-Helene, Bally, Cecile, Miekoutima, Elsa, Rahmé, Ramy, Lehmann-Che, Jacqueline, Ades, Lionel, Fenaux, Pierre, Cassinat, Bruno, Giraudier, Stephane
Publicado 2020

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy

por Prebet, Thomas, Cluzeau, Thomas, Park, Sophie, Sekeres, Mikkael A., Germing, Ulrich, Ades, Lionel, Platzbecker, Uwe, Gotze, Katharina, Vey, Norbert, Oliva, Esther, Sugrue, Mary M., Bally, Cecile, Kelaidi, Charikleia, Al Ali, Najla, Fenaux, Pierre, Gore, Steven D., Komrokji, Rami
Publicado 2017

Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy

por Pabst, Thomas, Vey, Norbert, Adès, Lionel, Bacher, Ulrike, Bargetzi, Mario, Fung, Samson, Gaidano, Gianluca, Gandini, Domenica, Hultberg, Anna, Johnson, Amy, Ma, Xuewen, Müller, Rouven, Nottage, Kerri, Papayannidis, Cristina, Recher, Christian, Riether, Carsten, Shah, Priya, Tryon, Jeffrey, Xiu, Liang, Ochsenbein, Adrian F.
Publicado 2023

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group

por Adès, Lionel, Thomas, Xavier, Bresler, Agnes Guerci, Raffoux, Emmanuel, Spertini, Olivier, Vey, Norbert, Marchand, Tony, Récher, Christian, Pigneux, Arnaud, Girault, Stephane, Deconinck, Eric, Gardin, Claude, Tournilhac, Olivier, Lambert, Jean Francois, Chevallier, Patrice, de Botton, Stephane, Lejeune, Julie, Dombret, Hervé, Chevret, Sylvie, Fenaux, Pierre
Publicado 2018

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

por Sekeres, Mikkael A., Watts, Justin, Radinoff, Atanas, Sangerman, Montserrat Arnan, Cerrano, Marco, Lopez, Patricia Font, Zeidner, Joshua F., Campelo, Maria Diez, Graux, Carlos, Liesveld, Jane, Selleslag, Dominik, Tzvetkov, Nikolay, Fram, Robert J., Zhao, Dan, Bell, Jill, Friedlander, Sharon, Faller, Douglas V., Adès, Lionel
Publicado 2021

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

por Sekeres, Mikkael A., Watts, Justin, Radinoff, Atanas, Sangerman, Montserrat Arnan, Cerrano, Marco, Lopez, Patricia Font, Zeidner, Joshua F., Campelo, Maria Diez, Graux, Carlos, Liesveld, Jane, Selleslag, Dominik, Tzvetkov, Nikolay, Fram, Robert J., Zhao, Dan, Bell, Jill, Friedlander, Sharon, Faller, Douglas V., Adès, Lionel
Publicado 2021

Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML

por Duchmann, Matthieu, Joudinaud, Romane, Boudry, Augustin, Pasanisi, Justine, Di Feo, Giuseppe, Kim, Rathana, Bucci, Maxime, Chauvel, Clémentine, Chat, Laureen, Larcher, Lise, Pacchiardi, Kim, Mathis, Stéphanie, Raffoux, Emmanuel, Adès, Lionel, Berthon, Céline, Clappier, Emmanuelle, Roumier, Christophe, Puissant, Alexandre, Preudhomme, Claude, Duployez, Nicolas, Itzykson, Raphaël
Publicado 2022

BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia

por Vidal, Valérie, Robert, Guillaume, Goursaud, Laure, Durand, Laetitia, Ginet, Clemence, Karsenti, Jean Michel, Luciano, Frederic, Gastaud, Lauris, Garnier, Georges, Braun, Thorsten, Hirsch, Pierre, Raffoux, Emmanuel, Nloga, Anne Marie, Padua, Rose Ann, Dombret, Hervé, Rohrlich, Pierre, Ades, Lionel, Chomienne, Christine, Auberger, Patrick, Fenaux, Pierre, Cluzeau, Thomas
Publicado 2017

Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia

por Lengline, Etienne, Drenou, Bernard, Peterlin, Pierre, Tournilhac, Olivier, Abraham, Julie, Berceanu, Ana, Dupriez, Brigitte, Guillerm, Gaelle, Raffoux, Emmanuel, de Fontbrune, Flore Sicre, Ades, Lionel, Balsat, Marie, Chaoui, Driss, Coppo, Paul, Corm, Selim, Leblanc, Thierry, Maillard, Natacha, Terriou, Louis, Socié, Gerard, de Latour, Regis Peffault
Publicado 2018